source
- Eli Lilly to acquire Merida Biosciences in up to $2.9 billion deal for precision antibody-degrading therapiesEli Lilly announced it will purchase Massachusetts‑based Merida Biosciences, adding a platform that can selectively degrade disease‑causing antibodies. The transaction could total up to $2.875 bil…
- Novartis and Bristol Myers pause multiple autoimmune CAR-T trials after serious immune adverse eventsNovartis and Bristol Myers Squibb announced a temporary halt to several CAR-T cell therapy trials targeting autoimmune diseases. The pause involves Novartis’s autologous CD19 CAR-T candidate rapca…